La chaîne d'options affiche les données clés des options sur actions de Cullinan Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Cullinan Therapeutics..

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Chaîne d'Options

CULLINAN THERAPEUTICS INC

Cullinan Therapeutics

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics Inc

Capgemini SE

News

Press Releases

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Health Care

Contracts

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Earnings

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

CGEM

ADC Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

CytomX Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Emergent BioSolutions

enGene Holdings

Gossamer Bio

I-MAB

Invivyd

Jade Biosciences

Keros Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Ocugen

Organogenesis Holdings

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Solid Biosciences

Verastem

XOMA Royalty

HC Wainwright & Co.

BTIG

Morgan Stanley

Stifel

Cullinan Oncology

Comments

Cullinan Therapeutics

Cullinan Therapeutics (CGEM) Options

Cullinan Therapeutics (NASDAQ:CGEM) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL